Decrease in symptoms, blood loss and uterine size with nafarelin acetate before abdominal hysterectomy: a placebo-controlled, double-blind study.

To evaluate the efficacy and safety of nafarelin before hysterectomy in a prospective placebo-controlled trial, we randomized 188 pre-menopausal women with uterine fibroids (n = 111), menometrorrhagia (n = 58) or pelvic pain (n = 19) to receive either nafarelin (200 micrograms twice daily as a nasal spray) or a placebo for 3 months before abdominal hysterectomy. The data analysis could be performed in 166 women, of whom 107 received nafarelin and 59 a placebo. Nafarelin led to a rise in blood haemoglobin (5.

Can progestin be limited to every third month only in postmenopausal women taking estrogen?

We evaluated whether a progestin, added for 14 days every 3 months to estrogen replacement therapy, is capable of preventing the development of endometrial hyperplasia in postmenopausal women during a treatment period of 2 years. Postmenopausal women (263) in 10 hospitals and medical centers in Finland participated in this non-randomized prospective multicenter trial. The women received estradiol valerate 2 mg daily for 84 days and 20 mg of medroxyprogesterone acetate daily for days 71-84 followed by seven drug-free tablets.

Use of medication during pregnancy--a prospective cohort study on use and policy of prescribing.

Pregnancy is associated with special problems with respect in selection of medication and dosage, primarily due to potential teratogenic or toxic effects on the fetus by the drug itself, and secondly due to the physiologic adjustments in the mother in response to pregnancy. This prospective survey was designed to record the use of medications and the policy of prescribing during the course of pregnancy. In total, 5851 pregnant women residing in a county in southwestern Finland during the period June 15, 1987 and June 14, 1988 were studied, which is 69% of the total amount of births in the same area.

Transdermal oestrogen replacement therapy in a Finnish population.

In an open, multicentre study, transdermal administration of oestradiol (E2) by means of skin patches was investigated in a Finnish patient population suffering from typical post-menopausal symptoms. A total of 249 women applied a patch twice weekly for 6 months. Whereas 85% of the subjects were experiencing hot flushes and 83.

Effects of levonorgestrel and desogestrel in low-dose oral contraceptive combinations on serum lipids, apolipoproteins A-I and B and glycosylated proteins.

Fasting serum lipids, apolipoproteins and glycosylated serum proteins were studied in 20 women before, after three months of treatment and two months after termination of treatment with oral contraceptives containing 30 micrograms ethinyloestradiol (EE) plus 150 micrograms levonorgestrel or desogestrel. Levonorgestrel + EE induced significant increases in total triglycerides (48%), apoB (19%) and the ratio apoB/apoA-I (18%) and no significant changes in HDL-cholesterol (8% decrease), apoA-I, % HDL-cholesterol, total cholesterol and serum glycosylated proteins. Desogestrel + EE induced significant increases in HDL-cholesterol (12%), % HDL-cholesterol (15%), triglycerides (35%) and apoA-I (20%), no changes in total cholesterol, apoB and glycosylated serum proteins and a significant decrease in the ratio apoB/apoA-I (17%).

Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.

The oral administration of 150 micrograms desogestrel and 30 micrograms ethinyl estradiol (EE2) increases (P less than 0.001) serum concentrations of sex-hormone-binding globulin (SHBG) and corticosteroid-binding globulin (CBG), whereas treatment with 150 micrograms levonorgestrel and 30 micrograms EE2 only increases serum CBG concentrations. No changes in serum albumin concentrations occurred during or after treatment with either preparation, and increases in SHBG and CBG returned to the pretreatment values 1 month after treatment ceased.

Effects of two oral contraceptive combinations, 0.125 mg desogestrel + 0.050 mg ethinylestradiol and 0.125 mg levonorgestrel + 0.050 mg ethinylestradiol on the adrenal function of healthy female volunteers.

The effects of the oral contraceptive combinations of 0.125 mg desogestrel + 0.050 mg ethinylestradiol (EE), and of 0.

Effect of diazepam on emergence from ketamine anaesthesia. A double-blind study.

The series comprises 109 healthy females aged 14-49 years (mean age 28 years) hospitalized for legal abortion or diagnostic curettage. The patients were premedicated with morphine-scopolamine 0.4-0.

'Patient failure' as a reliability model for the 'minipill': a clinical study.

A trial was carried out in 10 healthy women to study the effects of withdrawal of treatment with 0.5 mg lynestrenol per day, for 3 successive days during the pre-ovulatory phase, on the physiological properties of the cervical mucus, vaginal cytology and pituitary and ovarian functions. In most cases, the amount, Spinnbarkeit and ferning of the cervical mucus and sperm penetration remained the same as that before interruption of treatment.

A discrete multichanneal procedure for the chemical determination of urinary estrogens during pregnancy.

A colorimetric method, based on the Kober reaction, was adapted for the determination of urinary estrogens during pregnancy. The method yields final volumes for direct measurements by a multichannel computer-controlled photometer. The speed of the analysis was increased so that 100 samples can easily be completed by one laboratory technician as triplicate analyses during one working day.

ORAL IRON PROPHYLAXIS DURING PREGNANCY-A COMPARATIVE STUDY ON DIFFERENT DOSAGE REGIMENS.

The effect of oral iron prophylaxis on haemoglobin concentration (Hb) and haematocrit (Hct) has been studied in 300 pregnant women. From the 3rd to 4th month of pregnancy and until term the women were randomly treated with 100 mg or 200 mg ferrous iron daily respectively as sustained-release tablets (Duroferon Duretter ) or 200 mg ferrous iron as rapidly disintegrating tablets. All three treatments gave the same effect on Hb and Hct.

Biological effects of a new and potent progestagen. A clinical study.

The biological effects of a new synthetic progestagen, Org 2969 (13-ethyl-11-methylene-18,19-dinor-17 alpha-pregn-4-en-20-yn-17-ol) were studied in healthy normally menstruating women. Two of them were given 0.125 mg, five 0.

Effect of an oral contraceptive on the lysine-8-vasopressin test in the diagnostic evaluation of pituitary function.

A comparative study was performed on the plasma 11-hydroxycorticosteroids (11-OHCS) responses to lysine-8-vasopressin (LVP) before and during ingestion of an oral contraceptive wieh oestrogenic activity. A total of 19 healthy women with a normal menstrual cycle and normal plasma 11-OHCS content in blood samples at 8 a.m.

Prevention of intraperitoneal adhesions by dextran. Hydrocortisone and chymotrypsin. An experimental study.

The purpose of an experimental study in guineapigs was to prevent adhesion formation in the intra-abdominal space by simultaneous intraperitoneal infusion of hydrocortisone, dextran and chymotrypsin. An examination made three weeks after the operation revealed a highly significant (p less than 0.001) difference in favour of the dextran, dextran-chymotrypsin and dextran-chymotrypsin-hydrocortisone groups when compared with the NaC1 and control groups.

Studies on the effect of 17alpha-ethinyl-6-estrene-5alpha, 7beta-diol on menstrual cycle and plasma and urinary hormones in normal women.

Pharmacological tests on rats and dogs showed that a novel steroid substance, ORG OI-65 (code name for 17alpha-ethinyl-6-estrene-5alpha, 7beta-diol) has both progestational and estrogenic properties. The effect of this substance on menstrual cycle was studied on 13 healthy fertile women, who received 2 mg of ORG OI-65 daily for 20 consecutive days from the 5th day of cycle. The following parameters were studied during pretreatment and treatment cycles: bleeding pattern, plasma progesterone, urinary excretion of FSH, LH and estrone, vaginal cytology, cervical mucus, endometrium biopsy and basal body temperature.

Activities of aspartate and alanine aminotransferases and alkaline phosphatase in sera of healthy subjects.

The activities of serum aspartate aminotransferase (EC 2.6.1.

A continuous-flow method for the determination of the activity of serum alkaline phosphatase in diethanolamine buffer.

A procedure for determination of serum alkaline phosphatase activity (EC 3.1.3.